Respiratory Syncytial Virus Infection
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infection.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Arexvy — GlaxoSmithKline Biologicals S.A.
Arexvy by GlaxoSmithKline Biologicals S.A. has been authorised for use in the European Union for Respiratory Syncytial Virus infections.
-
EMA approval · 2026-07-21EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG
EMA has authorised Abrysvo, a bivalent recombinant RSV vaccine, for the prevention of respiratory syncytial virus infections.
-
EMA approval · 2026-06-04EMA Authorised: Enflonsia (clesrovimab) — Merck Sharp Dohme Limited
The EMA authorises Enflonsia (clesrovimab) from Merck Sharp & Dohme Limited for use in Respiratory Syncytial Virus vaccines.
-
EMA approval · 2026-04-24EMA Authorised: Beyfortus (nirsevimab) — Sanofi Winthrop Industrie
The European Medicines Agency authorised Beyfortus (nirsevimab) for prevention of respiratory syncytial virus infection in infants, with mar…
-
EMA approval · 2026-04-22EMA Authorised: Enflonsia (clesrovimab) — Merck Sharp Dohme Limited
The European Medicines Agency authorised Enflonsia (clesrovimab) from Merck Sharp & Dohme Limited for use against Respiratory Syncytial Viru…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-10EMA Authorised: Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)) — Pfizer Europe MA EEIG
The EMA authorised Abrysvo, Pfizer's bivalent recombinant RSV vaccine, for the prevention of respiratory syncytial virus infections in the E…
-
FDA approval · 2026-04-07FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)
FDA approved a supplemental application for Beyfortus (nirsevimab) submitted by Sanofi Vaccines US Inc.
-
EMA approval · 2025-12-12EMA Authorised: Synagis (palivizumab) — AstraZeneca AB
The EMA authorised Synagis (palivizumab) for respiratory syncytial virus infections, with AstraZeneca AB as the marketing authorisation hold…
-
FDA approval · 2025-10-20FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)
FDA approved a supplemental application for Beyfortus (nirsevimab) from Sanofi Vaccines US Inc., related to an update/expansion of the produ…
-
FDA approval · 2024-08-22FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)
FDA approved a supplemental application for BEYFORTUS (nirsevimab) from Sanofi Vaccines US Inc.
-
FDA approval · 2024-02-23FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)
The FDA approved a supplemental application for Beyfortus (nirsevimab) submitted by Sanofi Vaccines US Inc. The document notes the submissio…
-
EMA approval · 2023-07-21First RSV vaccine to protect infants up to 6 months of age and older adults
EMA announces the first RSV vaccine that can protect infants up to 6 months of age and older adults, marking a pivotal approval for RSV prev…
-
FDA approval · 2023-07-17FDA Approved: BEYFORTUS — Original Application (Sanofi Vaccines US Inc.)
FDA approved Beyfortus (nirsevimab) from an original application to prevent respiratory syncytial virus lower respiratory tract disease in h…
-
EMA approval · 2023-04-26First vaccine to protect older adults from respiratory syncytial virus (RSV) infection
The European Medicines Agency announces the first vaccine approved to protect older adults from Respiratory Syncytial Virus (RSV) infection.
-
FDA approval · 2017-05-12FDA Approved: SYNAGIS — Supplemental Application (Swedish Orphan Biovitrum AB (publ))
FDA approved a supplemental application for Synagis (palivizumab) from Swedish Orphan Biovitrum AB, indicating an approved change to the pro…
-
FDA approval · 2016-01-06FDA Approved: RIBAVIRIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ribavirin from Aurobindo Pharma Limited, authorizing continued approval and use of the ribavirin…
-
FDA approval · 2016-01-06FDA Approved: VIRAZOLE — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for Virazole (ribavirin) submitted by Bausch Health US, LLC, resulting in labeling changes as part o…
-
FDA approval · 2014-03-21FDA Approved: SYNAGIS — Supplemental Application (Swedish Orphan Biovitrum AB (publ))
The FDA approved a supplemental application for Synagis (palivizumab) submitted by Swedish Orphan Biovitrum AB (publ).
-
FDA approval · 2012-04-04FDA Approved: SYNAGIS — Supplemental Application (Swedish Orphan Biovitrum AB (publ))
The FDA approved a supplemental application for Synagis (palivizumab) filed by Swedish Orphan Biovitrum AB (publ). The action approves an up…
-
FDA approval · 2011-11-16FDA Approved: RIBAVIRIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ribavirin from Aurobindo Pharma Limited, authorizing the generic ribavirin product.
-
FDA approval · 2011-04-04FDA Approved: SYNAGIS — Supplemental Application (Swedish Orphan Biovitrum AB (publ))
The FDA approved a supplemental application for Synagis (palivizumab) filed by Swedish Orphan Biovitrum AB (publ).
-
FDA approval · 2011-03-16FDA Approved: RIBAVIRIN — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ribavirin by Aurobindo Pharma Limited (ANDA 079111).
-
FDA approval · 2009-09-17FDA Approved: RIBAVIRIN — Original Application (Aurobindo Pharma Limited)
FDA approved Ribavirin as an Original Application (ANDA) from Aurobindo Pharma Limited, authorizing a generic ribavirin product.
-
FDA approval · 2009-03-23FDA Approved: SYNAGIS — Supplemental Application (Swedish Orphan Biovitrum AB (publ))
FDA approved a supplemental application for Synagis (palivizumab) filed by Swedish Orphan Biovitrum AB (publ).
-
FDA approval · 2008-08-01FDA Approved: SYNAGIS — Supplemental Application (Swedish Orphan Biovitrum AB (publ))
FDA approved a supplemental application for SYNAGIS (palivizumab) submitted by Swedish Orphan Biovitrum AB (publ), resulting in an approved …